| Autor: |
Waarts MR; Gerstner Sloan Kettering Graduate Program in Biomedical Sciences.; Human Oncology and Pathogenesis Program.; Center for Hematologic Malignancies.; Center for Epigenetics Research, and., Stonestrom AJ; Human Oncology and Pathogenesis Program.; Center for Hematologic Malignancies.; Center for Epigenetics Research, and.; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Park YC; Human Oncology and Pathogenesis Program.; Center for Hematologic Malignancies.; Center for Epigenetics Research, and., Levine RL; Human Oncology and Pathogenesis Program.; Center for Hematologic Malignancies.; Center for Epigenetics Research, and.; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. |
| Abstrakt: |
Targeted therapies have come to play an increasingly important role in cancer therapy over the past two decades. This success has been made possible in large part by technological advances in sequencing, which have greatly advanced our understanding of the mutational landscape of human cancer and the genetic drivers present in individual tumors. We are rapidly discovering a growing number of mutations that occur in targetable pathways, and thus tumor genetic testing has become an important component in the choice of appropriate therapies. Targeted therapy has dramatically transformed treatment outcomes and disease prognosis in some settings, whereas in other oncologic contexts, targeted approaches have yet to demonstrate considerable clinical efficacy. In this Review, we summarize the current knowledge of targetable mutations that occur in a range of cancers, including hematologic malignancies and solid tumors such as non-small cell lung cancer and breast cancer. We outline seminal examples of druggable mutations and targeting modalities and address the clinical and research challenges that must be overcome to maximize therapeutic benefit. |
